Navigation Links
Hard to Treat Diseases (HTDS) Releases experimental results in the treatment of (MS) Multiple Sclerosis
Date:3/16/2009

BELGRADE, March 16 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com is pleased to announce that a group of investigators (lead by Professor Mirjana Stojiljkovic) from Department of Neurobiology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Serbia, (IBISS group) introduced a novel therapeutic approach in treatment of multiple sclerosis (MS), a severe, currently incurable, human disease. The effectiveness of this therapy is shown in experimental animals and has to be proven in people with MS, so that obtained results has to be considered as "experimental." Experimental data obtained on laboratory animals provide the following beneficial effects of the therapy:

    -   The severity of clinical signs of disease was significantly reduced
    -   The pathological changes in the myelin sheath (demyelination) were
        not detected
    -   The reduction of mononuclear cell infiltrates, composed of T cells
        and macrophages/microglia was observed in the spinal cord tissue
    -   The degree of disability was lowered
    -   The duration of the disease was notably shortened
    -   The percentage mortality in severe disease was radically reduced
        (70%)
    -   The severity of treatment side effects was low and disappeared after
        cessation of drug application

In 2005 IBISS group received a prestige reward - The first place and golden medal of Nikola Tesla at the International Festival of Innovations, Know-how and Creativity. The award can be viewed at the company's corporate web site www.htdsmedical.com

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet http://www.pinksheets.com/ filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks.

CONTACT: For medical and scientific dialogue inquiry only, please contact Andrea Zecevic Hbsc. Msci; via e-mail at azconsulting2001@gmail.com. Andrea Zecevic obtained her degrees at the University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and Serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Mexico Doctors Now Treating Brain and Prostate Cancer With RapidArc Radiotherapy Technology
2. First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy
3. New Treatments Improve Control for Severe Asthma
4. Video: Record Number of Patients Seek Laser Treatments to Take Light-Years Off Their Faces
5. Tens of Thousands of Back Pain Patients Overtreated in Six Health Plans, According to HealthCore Study
6. First treatment for muscular dystrophy in sight: Scientists successfully harness exon-skipping
7. Early results favorable for 5-day radiation treatment of early stage prostate cancer
8. Studies show children can complete treatment for peanut allergies and achieve long-term tolerance
9. Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks
10. HemAway(R) Launches FDA-Cleared Painless Hemorrhoid Treatment Device
11. Victorian Cosmetic Institute to offer Liposuction Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: